-- Hangzhou Diagens Biotechnology (HKG:2526) booked 67.1 million yuan in attributable loss for 2025, widening from a loss of 43.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.
The medical imaging products maker's shares gained nearly 3% in afternoon trade Thursday.
Loss per share was 0.84 yuan, compared with 0.55 yuan in 2024.
Revenue more than doubled year on year to 164.4 million yuan from 70.4 million yuan.